Pyxis Oncology Terminates ATM Offering Program and Reduces Capacity to $0

Filing content

The company terminated its continuous offering under the existing ATM program and reduced the maximum aggregate gross sales price to $0. No further shares may be sold without filing a new prospectus supplement.